SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion announced new preclinical data for EVX-04, an off-the-shelf…

Evaxion A/S · 6-K filed Jun 11, 2026 at 06:00 ET

At the news

BULLISHIMPACT 6/10

6-K filed Jun 11, 2026 at 06:00 ET

Evaxion announced new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, showing successful expression/secretion in human cells and specific immune responses with targeted cell-killing. Data will be presented at the EHA 2026 Congress on June 13. This is an early-stage, non-clinical milestone for a pre-revenue biotech with no financial figures or regulatory filing trigger, making it a modest positiveEntwicklung but not a material near-term catalyst.

  • EVX-04, an off-the-shelf therapeutic vaccine for AML, achieved complete expression and secretion in human cells, enabling immune recognition and activation
  • All 16 ERV antigen fragments included in EVX-04 drive specific immune responses in mice (in vivo) and human cells (in vitro) and induce targeted cell-killing
  • Poster presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden on June 13, 2026
  • Company states it is preparing regulatory filing for clinical testing

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access